CB1 RECEPTOR ACTIVATION IN THE BASOLATERAL AMYGDALA PRODUCES ANTINOCICEPTION IN ANIMAL MODELS OF ACUTE AND TONIC NOCICEPTION
- 11 April 2007
- journal article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 34 (5-6) , 439-449
- https://doi.org/10.1111/j.1440-1681.2007.04592.x
Abstract
1. Recent studies have suggested that the basolateral nucleus of the amygdala (BLA) participates in the processing of pain information, especially noxious somatic information. Cannabinoid receptors or CB1 mRNA are expressed more in the BLA than in other nuclei of the amygdala. Thus, the aim of the present study was to examine whether CB1 receptors in the BLA may be involved in modulating acute and/or tonic nociceptive processing. 2. Adult rats were exposed to intra-BLA microinjection of the cannabinoid receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo [1,2,3,-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate [WIN 55,212-2 (1, 2.5, 5 or 10 microg/side)] and subjected to the tail flick and formalin tests. 3. The rats demonstrated a dose-dependent increase in latency to withdraw from a thermal noxious stimulus in the tail flick test and a decrease in formalin-induced pain behaviours. The antinociceptive effects of the CB1 receptor agonist WIN 55,212-2 (10 microg/side) in both tests were attenuated in the presence of the selective CB1 receptor antagonist, N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3- carboxamide (AM251; 0.55 ng/side). Administration of the CB1 receptor antagonist AM251 (0.55, 5.5, or 55.5 ng/side) alone did not alter the nociceptive thresholds in either test. Bilateral microinjection of the selective CB2 receptor antagonist N-[(1S)-endo-1,3,3-trimethyl bicyclo [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528; 1 microg/side) had no effect on the antinociception produced by WIN 55,212-2, suggesting that the antinociceptive actions of WIN 55,212-2 are mediated by CB1 receptors. 4. The findings suggest the existence of a CB1-mediated inhibitory system in the BLA that, when activated, can diminish responsivity to acute and tonic noxious stimuli, but that normally has no tonic effect on the response threshold of these stimuli.Keywords
This publication has 47 references indexed in Scilit:
- INVOLVEMENT OF N‐METHYL‐d‐ASPARTATE RECEPTORS and NITRIC OXIDE IN THE ROSTRAL VENTROMEDIAL MEDULLA IN MODULATING MORPHINE PAIN‐INHIBITORY SIGNALS FROM THE PERIAQUEDUCTAL GREY MATTER IN RATSClinical and Experimental Pharmacology and Physiology, 2005
- Vasoactive intestinal peptide in the amygdala inhibits tail flick reflexes in ratsBrain Research, 2005
- The Amygdala and Persistent PainThe Neuroscientist, 2004
- The rodent amygdala contributes to the production of cannabinoid-induced antinociceptionNeuroscience, 2003
- Cannabinoid analgesiaPharmacology & Therapeutics, 2002
- Two distinctive antinociceptive systems in rats with pathological painNeuroscience Letters, 2000
- An examination of the central sites of action of cannabinoid-induced antinociception in the ratLife Sciences, 1995
- The formalin test: a validation of the weighted-scores method of behavioural pain ratingPain, 1993
- A Pharmacological Analysis of Levonantradol Antinociception in MiceThe Journal of Clinical Pharmacology, 1981
- The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and catsPain, 1977